Literature DB >> 19128204

The endocannabinoid system: a new molecular target for the treatment of tobacco addiction.

Maria Scherma1, Paola Fadda, Bernard Le Foll, Benoit Forget, Walter Fratta, Steven R Goldberg, Gianluigi Tanda.   

Abstract

Tobacco addiction is one of the leading preventable causes of mortality in the world and nicotine appears to be the main critical psychoactive component in establishing and maintaining tobacco dependence. Several lines of evidence suggest that the rewarding effects of nicotine, which underlie its abuse potential, can be modulated by manipulating the endocannabinoid system. For example, pharmacological blockade or genetic deletion of cannabinoid CB(1) receptors reduces or eliminates many behavioral and neurochemical effects of nicotine that are related to its addictive potential. This review will focus on the recently published literature about the role of the endocannabinoid system in nicotine addiction and on the endocannabinoid system as a novel molecular target for the discovery of medications for tobacco dependence.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19128204      PMCID： PMC3821699          DOI： 10.2174/187152708786927859

Source DB:  PubMed          Journal:  CNS Neurol Disord Drug Targets        ISSN： 1871-5273            Impact factor:   4.388


  240 in total

Review 1.  Addiction, dopamine, and the molecular mechanisms of memory.

Authors:  J D Berke; S E Hyman
Journal:  Neuron       Date:  2000-03       Impact factor: 17.173

Review 2.  Neurobiology of relapse to heroin and cocaine seeking: a review.

Authors:  Uri Shalev; Jeffrey W Grimm; Yavin Shaham
Journal:  Pharmacol Rev       Date:  2002-03       Impact factor: 25.468

3.  Cannabinoid CB1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse.

Authors:  G Cossu; C Ledent; L Fattore; A Imperato; G A Böhme; M Parmentier; W Fratta
Journal:  Behav Brain Res       Date:  2001-01-08       Impact factor: 3.332

4.  Allosteric modulation of the cannabinoid CB1 receptor.

Authors:  Martin R Price; Gemma L Baillie; Adèle Thomas; Lesley A Stevenson; Morag Easson; Richard Goodwin; Adèle McLean; Lorraine McIntosh; Gillian Goodwin; Glenn Walker; Paul Westwood; Julia Marrs; Fiona Thomson; Phillip Cowley; Arthur Christopoulos; Roger G Pertwee; Ruth A Ross
Journal:  Mol Pharmacol       Date:  2005-08-19       Impact factor: 4.436

5.  The novel cannabinoid CB1 receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats.

Authors:  Kelly S Sink; Peter J McLaughlin; Jodi Anne T Wood; Cara Brown; Pusheng Fan; V Kiran Vemuri; Yan Peng; Yan Pang; Teresa Olszewska; Teresa Olzewska; Ganesh A Thakur; Alex Makriyannis; Linda A Parker; John D Salamone
Journal:  Neuropsychopharmacology       Date:  2007-06-20       Impact factor: 7.853

6.  Are weight concerns predictive of smoking cessation? A prospective analysis.

Authors:  A W Meyers; R C Klesges; S E Winders; K D Ward; B A Peterson; L H Eck
Journal:  J Consult Clin Psychol       Date:  1997-06

7.  2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor.

Authors:  L Hanus; S Abu-Lafi; E Fride; A Breuer; Z Vogel; D E Shalev; I Kustanovich; R Mechoulam
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-20       Impact factor: 11.205

8.  Long-term potentiation of excitatory inputs to brain reward areas by nicotine.

Authors:  H D Mansvelder; D S McGehee
Journal:  Neuron       Date:  2000-08       Impact factor: 17.173

9.  Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation.

Authors:  Darren Fegley; Silvana Gaetani; Andrea Duranti; Andrea Tontini; Marco Mor; Giorgio Tarzia; Daniele Piomelli
Journal:  J Pharmacol Exp Ther       Date:  2004-12-03       Impact factor: 4.030

10.  Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice.

Authors:  A Zimmer; A M Zimmer; A G Hohmann; M Herkenham; T I Bonner
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-11       Impact factor: 11.205
View more
  16 in total

Review 1.  Preclinical Studies of Cannabinoid Reward, Treatments for Cannabis Use Disorder, and Addiction-Related Effects of Cannabinoid Exposure.

Authors:  Leigh V Panlilio; Zuzana Justinova
Journal:  Neuropsychopharmacology       Date:  2017-08-28       Impact factor: 7.853

Review 2.  Interactions between the endocannabinoid and nicotinic cholinergic systems: preclinical evidence and therapeutic perspectives.

Authors:  Maria Scherma; Anna Lisa Muntoni; Miriam Melis; Liana Fattore; Paola Fadda; Walter Fratta; Marco Pistis
Journal:  Psychopharmacology (Berl)       Date:  2016-01-04       Impact factor: 4.530

3.  Gender Differences in the Association between Marijuana and Menthol Cigarette Use among African American Adult Cigarette Smokers.

Authors:  LaTrice Montgomery; Monica Webb Hooper
Journal:  Subst Use Misuse       Date:  2020-04-07       Impact factor: 2.164

Review 4.  Neurobiological mechanisms involved in nicotine dependence and reward: participation of the endogenous opioid system.

Authors:  Fernando Berrendero; Patricia Robledo; José Manuel Trigo; Elena Martín-García; Rafael Maldonado
Journal:  Neurosci Biobehav Rev       Date:  2010-02-16       Impact factor: 8.989

5.  Comorbid Cannabis and Tobacco Use in Adolescents and Adults.

Authors:  Punitha Subramaniam; Erin McGlade; Deborah Yurgelun-Todd
Journal:  Curr Addict Rep       Date:  2016-06-01

6.  The anandamide transport inhibitor AM404 reduces the rewarding effects of nicotine and nicotine-induced dopamine elevations in the nucleus accumbens shell in rats.

Authors:  Maria Scherma; Zuzana Justinová; Claudio Zanettini; Leigh V Panlilio; Paola Mascia; Paola Fadda; Walter Fratta; Alexandros Makriyannis; Subramanian K Vadivel; Islam Gamaleddin; Bernard Le Foll; Steven R Goldberg
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

Review 7.  Inhibition of FAAH and activation of PPAR: new approaches to the treatment of cognitive dysfunction and drug addiction.

Authors:  Leigh V Panlilio; Zuzana Justinova; Steven R Goldberg
Journal:  Pharmacol Ther       Date:  2013-01-16       Impact factor: 12.310

Review 8.  Preclinical studies on the reinforcing effects of cannabinoids. A tribute to the scientific research of Dr. Steve Goldberg.

Authors:  Gianluigi Tanda
Journal:  Psychopharmacology (Berl)       Date:  2016-03-30       Impact factor: 4.530

9.  The future of endocannabinoid-oriented clinical research after CB1 antagonists.

Authors:  Bernard Le Foll; David A Gorelick; Steven R Goldberg
Journal:  Psychopharmacology (Berl)       Date:  2009-03-20       Impact factor: 4.530

10.  THC reduces the anticipatory nucleus accumbens response to reward in subjects with a nicotine addiction.

Authors:  J M Jansma; H H van Hell; L J M J Vanderschuren; M G Bossong; G Jager; R S Kahn; N F Ramsey
Journal:  Transl Psychiatry       Date:  2013-02-26       Impact factor: 6.222
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.